These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 464818)

  • 1. Heparin and antithrombin 3.
    Stein ZL
    Arch Surg; 1979 Aug; 114(8):980. PubMed ID: 464818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombin III (clinical aspects and methodology)].
    Abildgaard U
    Ric Clin Lab; 1978; 8 Suppl 2():90-7. PubMed ID: 106453
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significance of the amidolytic method in the typing of congenital antithrombin III deficiency].
    Losonczy H; Nagy I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):184-8. PubMed ID: 6177603
    [No Abstract]   [Full Text] [Related]  

  • 4. Antithrombin III in Echis carinatus envenomation in northern Nigeria.
    Mba EC; Onyemelukwe GC
    Acta Haematol; 1989; 81(2):98-100. PubMed ID: 2496558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithrombin III determinations in internal medicine and surgery].
    Schmitz-Huebner U
    Med Lab (Stuttg); 1980 Sep; 33(9):232-5. PubMed ID: 7442606
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antithrombin-III activity in clotting disorders in polytraumatized patients (author's transl)].
    Sefrin P; Brunswig D; Wenzel M
    Dtsch Med Wochenschr; 1982 Mar; 107(10):383-5. PubMed ID: 7060468
    [No Abstract]   [Full Text] [Related]  

  • 7. [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders].
    Hofmann M; Rest A; Hafner G; Tanner B; Brockerhoff P; Weilemann LS
    Anaesthesist; 1997 Aug; 46(8):689-96. PubMed ID: 9382207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heparin cofactor II studies in thrombophilic patients].
    Pál A; Sas G
    Orv Hetil; 1990 Mar; 131(9):461-2, 465. PubMed ID: 2179813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Importance of the determination of thrombin-antithrombin-III complexes in hypercoagulability states].
    García Avello A; García Frade A; Sureda JL; Torrado MC
    Sangre (Barc); 1991 Apr; 36(2):163. PubMed ID: 1866654
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prethrombosis in child malnutrition].
    Jiménez R; Jiménez E; Mora LA; Vargas W; Atmetlla F; Carrillo JM
    Arch Latinoam Nutr; 1980 Dec; 30(4):580-9. PubMed ID: 6793001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies on the determination of abnormal antithrombin III activity].
    Nagy I; Losonczy H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):180-3. PubMed ID: 6177602
    [No Abstract]   [Full Text] [Related]  

  • 13. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer.
    Aiach M; Léon M; Michaud A; Capron L
    Semin Thromb Hemost; 1983 Jul; 9(3):206-16. PubMed ID: 6351255
    [No Abstract]   [Full Text] [Related]  

  • 14. Timing of hypercoagulable screens.
    Kovacs MJ
    Arch Intern Med; 2002 Mar; 162(5):613-4. PubMed ID: 11871942
    [No Abstract]   [Full Text] [Related]  

  • 15. [From clinical tests to etiology: analysis of clinical features. Coagulation disorders].
    Sakuragawa N
    Rinsho Byori; 1987 Dec; Spec No 75():135-44. PubMed ID: 3448279
    [No Abstract]   [Full Text] [Related]  

  • 16. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Inhibition mechanism of blood coagulation--especially on the function of antithrombin III].
    Sakuragawa N
    Rinsho Byori; 1985 Sep; 33(9):974-81. PubMed ID: 3841167
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients.
    Pusineri F; Bini A; Mussoni L; Remuzzi G; Donati MB
    J Clin Pathol; 1980 Jul; 33(7):631-4. PubMed ID: 6776154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation.
    Hashimoto K; Yamagishi M; Sasaki T; Nakano M; Kurosawa H
    Ann Thorac Surg; 1994 Sep; 58(3):799-804; discussion 804-5. PubMed ID: 7944706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coagulation disorders in pregnancy toxemias and pre-eclampsia].
    Weenink GH; Treffers PE; ten Cate JW; Smorenberg-Schoorl ME
    Ned Tijdschr Geneeskd; 1984 Oct; 128(42):1985-9. PubMed ID: 6504187
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.